Juda Scott 4

What Happened

• Juda Scott, a director of Inmune Bio (INMB), exercised 14,801 common stock purchase warrants on July 2, 2026, paying $1.40 per share for a total cash outlay of $20,721 to acquire 14,801 common shares. The filing also reports a related derivative exercise/disposition line (code X) showing $0.13 per share, total $1,850, associated with the in‑the‑money warrants being exercised/converted.

Key Details

• Transaction date: July 2, 2026; Form 4 filed July 7, 2026.
• Purchase: 14,801 shares acquired at $1.40 each; total reported cash paid $20,721 (code M).
• Related derivative reporting: 14,801 derivative units reported disposed at $0.13 each (total $1,850; code X) reflecting the in‑the‑money exercise reporting.
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Footnote: The shares were acquired by exercising 50% of the April 2024 warrants held by Mr. Scott under an Inducement Letter. He agreed to exercise those 50% for cash at the reduced $1.40 price in exchange for the issuer extending the maturity of the remaining 50% of his April 2024 warrants from June 30, 2026 to December 31, 2027.
• Filing timeliness: Form 4 was filed July 7 covering the July 2 transaction; no late‑filing notation was indicated in the provided data.

Context

• This was a cash exercise of warrants (a purchase), not a sale. The X‑coded entry reflects the reporting mechanics for exercising an in‑the‑money derivative (the warrant) and the related value element; it does not indicate a separate open‑market sale of the underlying shares.
• Purchases/exercises by insiders can be informative to investors because they represent cash put into the company’s equity, but they do not by themselves indicate future performance.